Generic Pharmaceutical Industry Welcomes Canada’s Admission to Trans-pacific Partnership Negotiations

Asia-Pacific Region presents important market opportunities for Canadian generic pharmaceutical manufacturers

Toronto, October 9, 2012Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), today made the following statement regarding Canada’s admission to the Trans-Pacific Partnership (TPP) negotiations:

“The Canadian Generic Pharmaceutical Association congratulates the Government of Canada on formally joining the Trans-Pacific Partnership negotiations.

As an industry that is heavily dependent on trade, generic pharmaceutical manufacturers support the Government of Canada’s efforts to eliminate tariff and non-tariff barriers, and to expand trade opportunities for value-added manufacturers. Generic pharmaceutical manufacturers operate most of the pharmaceutical manufacturing capacity in Canada, and currently export high quality medicines to more than 115 countries.

The Asia-Pacific Region is an important source of pharmaceutical inputs and other raw materials for Canadian-made generic medicines. The region is also an important export market for Canadian generic pharmaceutical manufacturers and presents enormous potential for export growth. Made-in-Canada generic medicines are currently exported to most TPP member countries, including Australia, Malaysia, Mexico, New Zealand, Peru, Singapore, the United States and Vietnam.

The TPP should seek to ensure the sustainability of a vibrant generic pharmaceutical manufacturing presence in Canada and other TPP member countries, while not inadvertently impeding competition or creating new market access barriers that restrict generic pharmaceutical manufacturers from exporting to or from TPP countries, and accessing other important markets around the globe. The agreement should also seek to harmonize the health, safety and inspection standards for pharmaceuticals across TPP countries.

In addition, the final agreement must also ensure that patients in TPP countries can continue to have timely access to the cost-effective generic medicines they need to meet urgent care needs, and to maintain or improve their quality of life.

CGPA looks forward to working with the Government of Canada and other TPP members to ensure the final TPP text will achieve these important objectives.”

About the Canadian Generic Pharmaceutical Association
The Canadian Generic Pharmaceutical Association (CGPA) represents Canada’s generic pharmaceutical industry. The industry plays an important role in controlling health-care costs in Canada. Generic drugs are dispensed to fill 60 per cent of all prescriptions but account for only 25 per cent of the $22-billion Canadians spend annually on prescription medicines.

For more information, please contact:

Jeff Connell
Vice President, Corporate Affairs
Canadian Generic Pharmaceutical Association (CGPA)
Tel: (416) 223-2333
Mobile: (647) 274-3379